MUC1-EXPRESSING ADVANCED, RELAPSED AND/OR REFRACTORY SOLID TUMORS

Clinical trials for MUC1-EXPRESSING ADVANCED, RELAPSED AND/OR REFRACTORY SOLID TUMORS explained in plain language.

Never miss a new study

Get alerted when new MUC1-EXPRESSING ADVANCED, RELAPSED AND/OR REFRACTORY SOLID TUMORS trials appear

Sign up with your email to follow new studies for MUC1-EXPRESSING ADVANCED, RELAPSED AND/OR REFRACTORY SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug XYA02 takes on tough cancers in first human trial

Disease control Not yet recruiting

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

Matched conditions: MUC1-EXPRESSING ADVANCED, RELAPSED AND/OR REFRACTORY SOLID TUMORS

Phase: PHASE1, PHASE2 • Sponsor: XYone Therapeutics, Inc • Aim: Disease control

Last updated Jun 28, 2026 00:00 UTC

MUC1-EXPRESSING ADVANCED, RELAPSED AND/OR REFRACTORY SOLID TUMORS

Get alerted when new MUC1-EXPRESSING ADVANCED, RELAPSED AND/OR REFRACTORY SOLID TUMORS trials appear

New drug XYA02 takes on tough cancers in first human trial